I'm not going to link to it because non-subscriber
Post# of 72433
![Avatar](/images/ProfileImages/424989898_3046_Avatar jpeg2.jpg)
But what was interesting was -- they said that NOVEL drugs had a much easier time getting patients. The CAR-T drugs are all so similar that they're competing for the same population. The novel drugs attract different kinds of patients.
Plus let's remember that the side effects with the CAR-T drugs have killed some people.
Kevetrin, of course, is a NOVEL drug.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)